FLAVOXATE HYDROCHLORIDE tablet, film coated

FLAVOXATE HYDROCHLORIDE by

Drug Labeling and Warnings

FLAVOXATE HYDROCHLORIDE by is a Prescription medication manufactured, distributed, or labeled by Carilion Materials Management. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

SPL UNCLASSIFIED SECTION

PRESCRIBING INFORMATION

DESCRIPTION

Flavoxate HCl tablets contain flavoxate hydrochloride, a synthetic urinary tract spasmolytic.

Chemically, flavoxate hydrochloride is 2-piperidinoethyl 3-methyl-4-oxo-2-phenyl-4 -1-benzopyran-8-carboxylate hydrochloride. The empirical formula of flavoxate hydrochloride is C H NO HCl. The molecular weight is 427.94. The structural formula appears below: H24254

Flavoxate HCl is supplied in tablets for oral administration. Each round, white, film-coated Flavoxate HCl tablet is debossed "PAD" and "0115" on one side and plain on the other side and contains flavoxate hydrochloride, 100 mg. Inactive ingredients consist of colloidal silicon dioxide, ethyl acrylate, hypromellose, lactose monohydrate, magnesium stearate, methyl methacrylate, microcrystalline cellulose, nonoxynol 100 and sodium starch glycolate. Film coating is composed of hypromellose 2910 6cP and polyethylene glycol.

CLINICAL PHARMACOLOGY

Flavoxate hydrochloride counteracts smooth muscle spasm of the urinary tract and exerts its effect directly on the muscle.

In a single study of 11 normal male subjects, the time to onset of action was 55 minutes. The peak effect was observed at 112 minutes. 57% of the flavoxate HCl was excreted in the urine within 24 hours.

INDICATIONS AND USAGE

Flavoxate HCl tablets are indicated for symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis. Flavoxate HCl tablets are not indicated for definitive treatment, but are compatible with drugs used for the treatment of urinary tract infections.

CONTRAINDICATIONS

Flavoxate HCl tablets are contraindicated in patients who have any of the following obstructive conditions: pyloric or duodenal obstruction, obstructive intestinal lesions or ileus, achalasia, gastrointestinal hemorrhage and obstructive uropathies of the lower urinary tract.

WARNINGS

Flavoxate HCl should be given cautiously in patients with suspected glaucoma.

PRECAUTIONS

Information for Patients:

Patients should be informed that if drowsiness and blurred vision occur, they should not operate a motor vehicle or machinery or participate in activities where alertness is required.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

Mutagenicity studies and long-term studies in animals to determine the carcinogenic potential of flavoxate HCl have not been performed.

Pregnancy:

Teratogenic Effects–Pregnancy Category B.

Reproduction studies have been performed in rats and rabbits at doses up to 34 times the human dose and revealed no evidence of impaired fertility or harm to the fetus due to flavoxate HCl. There are, however, no well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers:

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when flavoxate HCl is administered to a nursing woman.

Pediatric Use:

Safety and effectiveness in children below the age of 12 years have not been established.

ADVERSE REACTIONS

The following adverse reactions have been observed, but there are not enough data to support an estimate of their frequency.

Nausea, vomiting, dry mouth. Gastrointestinal:

Vertigo, headache, mental confusion, especially in the elderly, drowsiness, nervousness. CNS:

Leukopenia (one case which was reversible upon discontinuation of the drug). Hematologic:

Tachycardia and palpitation. Cardiovascular:

Urticaria and other dermatoses, eosinophilia and hyperpyrexia. Allergic:

Increased ocular tension, blurred vision, disturbance in eye accommodation. Ophthalmic:

Dysuria. Renal:

OVERDOSAGE

The oral LD for flavoxate HCl in rats is 4273 mg/kg. The oral LD for flavoxate HCl in mice is 1837 mg/kg. 5050

It is not known whether flavoxate HCl is dialyzable.

DOSAGE AND ADMINISTRATION

Adults and children over 12 years of age:

One or two 100 mg tablets 3 or 4 times a day. With improvement of symptoms, the dose may be reduced. This drug cannot be recommended for infants and children under 12 years of age because safety and efficacy have not been demonstrated in this age group.

HOW SUPPLIED

NDC: 68151-3826-0 in a PACKAGE of 1 TABLET, FILM COATEDS

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]

SPL UNCLASSIFIED SECTION

Manufactured For Perrigo® Minneapolis, MN 55427

Manufactured by: Mikart, INC. Atlanta, GA 30318

Code 917A00

7H700 RC J1

Rev 03-14 A

Flavoxate HCL 100 MG TAB

INGREDIENTS AND APPEARANCE

FLAVOXATE HYDROCHLORIDE 
flavoxate hydrochloride tablet, film coated

Product Information
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC: 68151-3826(NDC: 0574-0115)
Route of Administration	ORAL

Active Ingredient/Active Moiety
Ingredient Name	Basis of Strength	Strength
FLAVOXATE HYDROCHLORIDE (UNII: 9C05J6089W) (FLAVOXATE - UNII:3E74Y80MEY)	FLAVOXATE HYDROCHLORIDE	100 mg

Inactive Ingredients
Ingredient Name	Strength
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
ETHYL ACRYLATE (UNII: 71E6178C9T)
HYPROMELLOSES (UNII: 3NXW29V3WO)
LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)
MAGNESIUM STEARATE (UNII: 70097M6I30)
METHYL METHACRYLATE (UNII: 196OC77688)
CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)
NONOXYNOL-100 (UNII: A906T4D368)
SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)
HYPROMELLOSE 2910 (6 MPA.S) (UNII: 0WZ8WG20P6)
POLYETHYLENE GLYCOLS (UNII: 3WJQ0SDW1A)

Product Characteristics
Color	WHITE	Score	no score
Shape	ROUND	Size	11mm
Flavor		Imprint Code	PAD;0115
Contains

Packaging
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC: 68151-3826-0	1 in 1 PACKAGE

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA076831	12/22/2004

Labeler - Carilion Materials Management (079239644)

Registrant - Carilion Materials Management (079239644)

Establishment
Name	Address	ID/FEI	Business Operations
Carilion Materials Management		079239644	REPACK(68151-3826)